Filing Details

Accession Number:
0001493152-20-001239
Form Type:
13G Filing
Publication Date:
2020-01-28 16:15:31
Filed By:
Stonehenge Partners Llc
Company:
Qualigen Therapeutics Inc. (NASDAQ:QLGN)
Filing Date:
2020-01-28
SEC Url:
13G Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Stonehenge Partners 6. 119,197 8. 119,197 119,197 0.6%
Andrew J. Ritter 215,675 119,197 215,675 119,197 334,872 1.7%
Ira E. Ritter 139,550 119,822 139,550 119,822 259,372 1.3%
Filing

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934

(Amendment No. 2)*

 

Ritter Pharmaceuticals, Inc.

(Name of Issuer)

 

Common Stock, par value $0.001 per share

(Title of Class of Securities)

 

767836109

(CUSIP Number)

 

December 31, 2019

(Date of Event That Requires Filing of This Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

[  ] Rule 13d-1 (b)

 

[  ] Rule 13d-1 (c)

 

[X] Rule 13d-1 (d)

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

   

 

CUSIP No. 767836109 SCHEDULE 13G PAGE 1 OF 5

 

1.

NAMES OF REPORTING PERSONS

 

Stonehenge Partners LLC

 

 
2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

 

(a) [  ]

(b) [  ]

3.

SEC USE ONLY

 

 
4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

United States

 

 

 

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY

EACH
REPORTING
PERSON WITH

5.

SOLE VOTING POWER

 

6.

SHARED VOTING POWER

 

119,197 (1)

 

7.

SOLE DISPOSITIVE POWER

 

8.

SHARED DISPOSITIVE POWER

 

119,197 (1)

 

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

119,197 (1)

 

10.

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [  ]

 

(SEE INSTRUCTIONS)

 

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

0.6% (2)

 

12.

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

 

OO

 

 

(1) Represents 100,447 shares owned directly and 18,750 shares underlying warrants that are exercisable as of December 31, 2019.

(2) Based on 19,108,331 shares of Common Stock of the Company outstanding as of December 31, 2019.

 

   

 

CUSIP No. 767836109 SCHEDULE 13G PAGE 2 OF 5

 

1.

NAMES OF REPORTING PERSONS

 

Andrew J. Ritter

 

 
2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

 

(a) [  ]

(b) [  ]

3.

SEC USE ONLY

 

 
4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

United States

 

 

 

NUMBER OF SHARES BENEFICIALLY OWNED BY

EACH REPORTING PERSON WITH

5.

SOLE VOTING POWER

 

215,675 (1)

 

6.

SHARED VOTING POWER

 

119,197 (2)

 

7.

SOLE DISPOSITIVE POWER

 

215,675 (1)

 

8.

SHARED DISPOSITIVE POWER

 

119,197 (2)

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

334,872

 

10.

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [  ]

 

(SEE INSTRUCTIONS)

 

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

1.7% (3)

 

12.

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

 

IN

 

 

(1) Represents 625 shares owned directly and 215,050 shares underlying stock option awards that are currently exercisable or exercisable within 60 days of December 31, 2019.

 

(2) As a managing partner of Stonehenge Partners LLC, Andrew Ritter may be deemed the beneficial owner of these shares.

 

(3) Based on 19,108,331 shares of Common Stock of the Company outstanding as of December 31, 2019.

 

   

  

CUSIP No. 767836109 SCHEDULE 13G PAGE 3 OF 5

 

1.

NAMES OF REPORTING PERSONS

 

Ira E. Ritter

 

 
2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

 

(a) [  ]

(b) [  ]

3.

SEC USE ONLY

 

 
4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

United States

 

 

 

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY

EACH
REPORTING

PERSON WITH

5.

SOLE VOTING POWER

 

139,550 (1)

 

6.

SHARED VOTING POWER

 

119,822 (2)

 

7.

SOLE DISPOSITIVE POWER

 

139,550 (1)

 

8.

SHARED DISPOSITIVE POWER

 

119,822 (2)

 

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

259,372

 

10.

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [  ]

 

(SEE INSTRUCTIONS)

 

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

1.3% (3)

 

12.

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

 

IN

 

 

(1) Shares underlying stock option awards that are currently exercisable or exercisable within 60 days of December 31, 2019.

 

(2) As a managing partner of Stonehenge Partners LLC, Ira Ritter may be deemed the beneficial owner of the shares held by Stonehenge Partners LLC. In addition, this number includes 625 shares held in a retirement plan trust of which the reporting person and his spouse are trustees.

 

(3) Based on 19,108,331 shares of Common Stock of the Company outstanding as of December 31, 2019.

 

   

 

CUSIP No. 767836109 SCHEDULE 13G PAGE 4 OF 5

 

Item 1(a).   Name of Issuer:
     
    Ritter Pharmaceuticals, Inc. (the “Company”)
     
Item 1(b).   Address of Issuer’s Principal Executive Offices:
     
   

1880 Century Park East, #1000

Los Angeles, CA 90067

     
Item 2(a).   Name of Person(s) Filing:
     
   

Stonehenge Partners LLC

Andrew J. Ritter

Ira E. Ritter

     
Item 2(b).   Address of Principal Business Office, or, if None, Residence:
     
   

Stonehenge Partners LLC - 31800 Oxnard Street, Suite 250, Woodland Hills, California 91367

 

Andrew J. Ritter and Ira E. Ritter – c/o Ritter Pharmaceuticals, Inc., 1880 Century Park East, #1000, Los Angeles, CA 90067

     
Item 2(c).   Citizenship:
     
   

Stonehenge Partners LLC is a California limited liability company with its principal place of business in California.

 

Andrew J. Ritter - United States

 

Ira E. Ritter – United States

     
Item 2(d).   Title of Class of Securities:Not Applicable
     
    Common Stock, par value $0.001 per share
     
Item 2(e).   CUSIP Number:
     
    767836109
     
Item 3.   If This Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing is a:
     
    Not Applicable

 

   

 

CUSIP No. 767836109 SCHEDULE 13G PAGE 5 OF 5

 

Item 4.   Ownership:
     
   

The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person and is incorporated herein by reference.

 

As managing partners of Stonehenge Partners LLC, Andrew Ritter and Ira Ritter may be deemed beneficial owners of the shares held by Stonehenge Partners LLC insofar as they may be deemed to share the power to direct the voting or disposition of such shares. Neither the filing of this Schedule 13G, any amendment hereto, nor any of their respective contents shall be deemed to constitute an admission that either of such individuals is, for any purpose, the beneficial owner of such securities, and such beneficial ownership is expressly disclaimed. The filing of this statement should not be construed to be an admission that any of the Reporting Persons are members of a “group” for the purposes of Sections 13(d) and 13(g) of the Act.

 

Item 5.   Ownership of Five Percent or Less of a Class.
     
    Not Applicable
     
Item 6.   Ownership of More than Five Percent on Behalf of Another Person.
     
   

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [X].

     
Item 7.   Identification and Classification of the Subsidiary That Acquired the Security Being Reported by the Parent Holding Company or Control Person.
     
    Not Applicable
     
Item 8.   Identification and Classification of Members of the Group.
     
    Not Applicable
     
Item 9.   Notice of Dissolution of the Group.
     
    Not Applicable
     
Item 10.   Certification:
     
    Not Applicable

 

   

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Date: January 28, 2020 Stonehenge Partners LLC
     
  By: /s/ Andrew J. Ritter
  Name: Andrew J. Ritter
  Title: Managing Partner
     
Date: January 28, 2020 By: /s/ Andrew J. Ritter
    Andrew J. Ritter
     
Date: January 28, 2020 By: /s/ Ira E. Ritter
    Ira E. Ritter